Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Ritz

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2023
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedbackCamila H Coelho, Nathaniel Bloom, Sydney I Ramirez, et al.
Open Forum Infectious Diseases|December 5, 2022
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19Carlee Moser, Jonathan Z Li, Joseph J Eron, et al.
JCI Insight|November 15, 2022
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responsesSydney I Ramirez, Alba Grifoni, Daniela Weiskopf, et al.
The Journal of Infectious Diseases|August 31, 2023
Variant-Specific Viral Kinetics in Acute COVID-19Ruy M Ribeiro, Manish C Choudhary, Rinki Deo, et al.
JCI Insight|December 20, 2024
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 22, 2024
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody FeedbackNathaniel Bloom, Sydney I Ramirez, Hallie Cohn, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Pathogens & Immunity|May 15, 2024
Safety, Efficacy, and Pharmacokinetics of Combination SARS-CoV-2 Neutralizing Monoclonal Antibodies BMS-986414 (C135-LS) and BMS-986413 (C144-LS) Administered Subcutaneously in Non-Hospitalized Persons with COVID-19 in a Phase 2 TrialKatya C Corado, Kara W Chew, Mark J Giganti, et al.
Biorxiv : the Preprint Server for Biology|December 4, 2023
SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedbackCamila H Coelho, Nathaniel Bloom, Sydney I Ramirez, et al.
Open Forum Infectious Diseases|December 5, 2022
Predictors of SARS-CoV-2 RNA From Nasopharyngeal Swabs and Concordance With Other Compartments in Nonhospitalized Adults With Mild to Moderate COVID-19Carlee Moser, Jonathan Z Li, Joseph J Eron, et al.
JCI Insight|November 15, 2022
Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responsesSydney I Ramirez, Alba Grifoni, Daniela Weiskopf, et al.
The Journal of Infectious Diseases|August 31, 2023
Variant-Specific Viral Kinetics in Acute COVID-19Ruy M Ribeiro, Manish C Choudhary, Rinki Deo, et al.
JCI Insight|December 20, 2024
Early antiviral CD4+ and CD8+ T cells are associated with upper airway clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
The Journal of Infectious Diseases|July 19, 2024
Safety and Efficacy of SAB-185 for Nonhospitalized Adults With COVID-19: A Randomized Clinical TrialKara W Chew, Babafemi O Taiwo, Carlee Moser, et al.
Biorxiv : the Preprint Server for Biology|November 14, 2023
Early antiviral CD4 and CD8 T cell responses and antibodies are associated with upper respiratory tract clearance of SARS-CoV-2Sydney I Ramirez, Paul G Lopez, Farhoud Faraji, et al.
Iscience|March 24, 2025
Tixagevimab/cilgavimab or placebo for COVID-19 in ACTIV-2: Safety, pharmacokinetics and neutralizing and anti-drug antibodiesRachel A Bender Ignacio, Kara W Chew, Carlee Moser, et al.
The Journal of Infectious Diseases|July 22, 2024
SARS-CoV-2 Monoclonal Antibody Treatment Followed by Vaccination Shifts Human Memory B-Cell Epitope Recognition, Suggesting Antibody FeedbackNathaniel Bloom, Sydney I Ramirez, Hallie Cohn, et al.
Pageof 6